company background image
SYRS logo

Syros Pharmaceuticals NasdaqGS:SYRS Stock Report

Last Price

US$5.84

Market Cap

US$151.9m

7D

-7.7%

1Y

109.3%

Updated

27 Mar, 2024

Data

Company Financials +

Syros Pharmaceuticals, Inc.

NasdaqGS:SYRS Stock Report

Market Cap: US$151.9m

SYRS Stock Overview

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies.

SYRS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Syros Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Syros Pharmaceuticals
Historical stock prices
Current Share PriceUS$5.84
52 Week HighUS$8.17
52 Week LowUS$2.09
Beta1.79
1 Month Change-22.03%
3 Month Change-18.89%
1 Year Change109.32%
3 Year Change-92.19%
5 Year Change-94.01%
Change since IPO-96.78%

Recent News & Updates

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Jan 14

Recent updates

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Jan 14

Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

Sep 20

Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609

Sep 13

Syros Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Syros Pharmaceuticals Is A Buy As New Trials Start

Nov 20

Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Nov 08
Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 02
Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Will Probably Find It Hard To See A Huge Raise This Year

Syros Pharma up 18% day after ARK Innovation dumps shares

May 27

Analysts Just Made A Substantial Upgrade To Their Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Forecasts

May 11
Analysts Just Made A Substantial Upgrade To Their Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Forecasts

Does Syros Pharmaceuticals (NASDAQ:SYRS) Have A Healthy Balance Sheet?

May 07
Does Syros Pharmaceuticals (NASDAQ:SYRS) Have A Healthy Balance Sheet?

Can You Imagine How Syros Pharmaceuticals' (NASDAQ:SYRS) Shareholders Feel About The 57% Share Price Increase?

Mar 02
Can You Imagine How Syros Pharmaceuticals' (NASDAQ:SYRS) Shareholders Feel About The 57% Share Price Increase?

What Kind Of Investors Own Most Of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)?

Jan 26
What Kind Of Investors Own Most Of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)?

Shareholder Returns

SYRSUS BiotechsUS Market
7D-7.7%0.9%0.4%
1Y109.3%10.3%28.8%

Return vs Industry: SYRS exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: SYRS exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is SYRS's price volatile compared to industry and market?
SYRS volatility
SYRS Average Weekly Movement9.2%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: SYRS's share price has been volatile over the past 3 months.

Volatility Over Time: SYRS's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011117Conley Cheehttps://www.syros.com

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd.

Syros Pharmaceuticals, Inc. Fundamentals Summary

How do Syros Pharmaceuticals's earnings and revenue compare to its market cap?
SYRS fundamental statistics
Market capUS$151.88m
Earnings (TTM)-US$164.57m
Revenue (TTM)US$9.94m

15.3x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SYRS income statement (TTM)
RevenueUS$9.94m
Cost of RevenueUS$0
Gross ProfitUS$9.94m
Other ExpensesUS$174.51m
Earnings-US$164.57m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-6.33
Gross Margin100.00%
Net Profit Margin-1,656.34%
Debt/Equity Ratio247.4%

How did SYRS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.